(NASDAQ: RCKT) Rocket Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 46%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.09%.
Rocket Pharmaceuticals's earnings in 2025 is -$240,912,000.On average, 17 Wall Street analysts forecast RCKT's earnings for 2025 to be -$230,112,923, with the lowest RCKT earnings forecast at -$243,932,902, and the highest RCKT earnings forecast at -$221,585,012. On average, 16 Wall Street analysts forecast RCKT's earnings for 2026 to be -$172,755,143, with the lowest RCKT earnings forecast at -$194,085,744, and the highest RCKT earnings forecast at -$147,723,341.
In 2027, RCKT is forecast to generate -$143,134,719 in earnings, with the lowest earnings forecast at -$213,176,145 and the highest earnings forecast at -$84,088,671.